<DOC>
	<DOCNO>NCT01699217</DOCNO>
	<brief_summary>The GIMEMA CML Working Party promote multicentre , observational , prospective study CML patient treat frontline NIL . Patients follow 5 year . This study help definition guideline treatment CML patient early CP .</brief_summary>
	<brief_title>Front-line Nilotinib Treatment BCR-ABL+ Chronic Myeloid Leukaemia Chronic Phase</brief_title>
	<detailed_description>The primary objective study describe stability molecular response NIL frontline therapy newly diagnose , unselected , CP CML patient , independent , investigator-initiated observational study . Imatinib mesylate ( IM ) , protein tyrosine kinase inhibitor ( TKI ) target BCR-ABL , become last decade standard care Chronic Myeloid Leukaemia ( CML ) chronic phase ( CP ) 1,2 . Nilotinib ( NIL ) second generation TKI , effective IM-resistant IM-intolerant patient , demonstrate superior efficacy IM early CP BCR-ABL+ CML patients3 . Currently , important target treatment CML TKIs major molecular response ( MMR ) , define â‰¥ 3 log reduction BCR-ABL/ABL transcript level , marker well long-term outcome . With imatinib therapy , achieve MMR correlate improve probability durable cytogenetic remission30 . Results IRIS suggest MMR 12 month imatinib therapy may marker stable response . Further , IRIS study show patient MMR 12 month therapy significantly good probability disease-free survival compare complete cytogenetic remission , MMR31 . Moreover , obtain undetectable BCR-ABL transcript level extremely relevant order consider TKIs discontinuation . This condition know `` Complete Molecular Response '' ( CMR ) define accord sensitivity achieve ( definition see `` Criteria evaluation '' section ) . As far treatment discontinuation , two experience publish far , aim evaluate persistence CMR imatinib discontinuation . The first pilot study32 12 patient include . These 12 patient discontinue imatinib least 2 year CMR ( median duration negativity , 32 month ) . Six patient display molecular relapse detectable BCR-ABL transcript 1 , 1 , 2 , 3 , 4 , 5 month . Imatinib reintroduce lead novel molecular response . Six patient ( 50 % ) still undetectable level BCR-ABL transcript median follow-up 18 month ( range , 9-24 month ) . The result pilot trial confirm extended second trial , STIM trial33 : 100 patient enrol , median follow-up 17 month , 69 patient least 12 month follow-up : 42 ( 61 % ) 69 patient relapse ( 40 6 month , one patient month 7 , one month 19 ) . At 12 month , probability persistent CMR 69 patient 41 % ( 95 % CI 29-52 ) . All patient relapse responded reintroduction imatinib . An increase CMR rate could possibly translate high proportion patient candidate stop anti-CML treatment , high probability remain disease-free long term . The advantage possible future scenario could : first , possibility treatment discontinuation least patient chronic clinical adverse event ; second , potential reduction cost TKI treatment ( introduction TKI , cost CML treatment increase year year , increase prevalence CML patient ) . Standardized molecular monitoring become widely available Europe effort EUTOS cooperation19 allow generation comparable data residual disease use recalculation international scale despite data analyze many different laboratory . These advance standardization molecular response improvement target therapy allow comparable response assessment across Italian Centres early treatment optimization patient . In summary , 1 ) monitoring molecular response deep sustain molecular response , provide straightforward opportunity ass patient ' response possible prognosis use target therapy . 2 ) Most data second generation TKIs company-sponsored study generally implement select referral centre . 3 ) The detailed description kinetic molecular response , particularly , rate stable MR4 , potentially related turn subsequent treatment discontinuation , within frame long-term post-marketing surveillance observational trial offer eligible patient follow nation-wide , independent multicentre group core distinctive feature observational trial .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>Age : &gt; =18 year ; Patients chronic phase Ph+ and/or BCRABL+ CML , newly diagnose ( less 6 month ) ; Prior treatment Hydroxyurea Anagrelide allow ; Prior treatment IM le 30 day allow ; Signed write inform const accord ICH/EU/GCP national local law . Patients pregnant ( negative pregnancy test request within 2 day nilotinib start ) breast feeding , adult reproductive potential employ effective method birth control . Newly diagnose Ph+ and/or BCRABL+ CML patient advanced phase ( accelerate blastic phase ) . Prior treatment nilotinib , dasatinib , tyrosinekinase inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic Myeloid Leukaemia</keyword>
	<keyword>Philadelphia positive</keyword>
	<keyword>BCR-ABL positive</keyword>
</DOC>